HDB Financial Services Q2 FY27 Profit Jumps 34% YoY as Disbursements Rise 18%
HDB Financial Services posted a strong Q2 FY27 performance, driven by an 18% YoY growth in disbursements and a 34% YoY increase in profit after tax. The company benefits from solid credit growth across retail segments and improving asset quality metrics heading into H2 FY27.
Market snapshot: HDB Financial Services released its Q2 FY27 earnings call transcript, highlighting strong operational execution. Net profit after tax expanded by 34% YoY alongside an 18% YoY rise in disbursements. Management signaled a positive outlook for the second half of the fiscal year supported by seasonal festive credit demand.
Data Snapshot
- Net profit after tax grew 34.2% YoY to ₹780 crore in Q2 FY27 compared to ₹581 crore in Q2 FY26.
- Loan disbursements expanded by 18% YoY during Q2 FY27, bolstering total loan book growth.
- Gross Stage 3 asset quality metric improved to 2.43% from 2.81% in the prior-year period.
What's Changed
- Net profit after tax increased from ₹581 crore in Q2 FY26 to ₹780 crore in Q2 FY27.
- Gross Stage 3 loan ratio decreased from 2.81% to 2.43% YoY.
Key Takeaways
- Disbursements surged 18% YoY in Q2 FY27, demonstrating resilient consumer credit demand.
- PAT rose 34% YoY to ₹780 crore due to expanding net interest income and reduced provision burden.
- Asset quality metrics strengthened with Gross Stage 3 loans declining to 2.43%.
- Management expects festive demand to maintain disbursement momentum into the second half of FY27.
SAHI Perspective
HDB Financial Services' Q2 FY27 performance reflects robust underlying loan demand in retail finance and vehicle lending. The dual driver of 18% disbursement growth and a 38 bps improvement in Gross Stage 3 assets underlines disciplined risk management while expanding market share.
Market Implications
Strong disbursement figures and asset quality recovery indicate healthy retail credit appetite across non-banking finance companies. Well-capitalized NBFCs with parentage support remain favorably placed to capture festive demand.
Trading Signals
Market Bias: Bullish
Robust operational delivery anchored by 18% YoY disbursement growth and a 34% YoY profit surge to ₹780 crore provides strong fundamental support.
Overweight: Diversified NBFCs, Retail Lending
Trigger Factors:
- Sustained credit uptake during H2 festive season
- Maintenance of Gross Stage 3 asset quality below 2.5%
Time Horizon: Medium-term (3-12 months)
Industry Context
India's NBFC sector continues to experience healthy credit demand across vehicle, consumer, and micro-enterprise loans. Improved collection efficiencies and lower provisioning costs support margin expansion for retail lenders.
Key Risks to Watch
- Unexpected rise in retail credit defaults during macroeconomic slowdowns
- Intense competition from commercial banks in consumer lending segments
Recent Developments
HDB Financial Services reported a 34% YoY increase in Q2 FY27 net profit to ₹780 crore, supported by a 12% expansion in its total loan book to ₹1.24 lakh crore.
Closing Insight
Sustained disbursement growth coupled with asset quality improvement equips HDB Financial Services to capture seasonal tailwinds effectively across H2 FY27.
High Performance Trading with SAHI.
Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.
Open Free AccountRelated
RailTel Wins ₹47.4 Crore Haryana State Electronics Network Installation Contract
Quality Power Starts Production At New Coil Factory In Sangli
Venus Pipes Starts Pipe Spooling Early, Secures ₹185 Crore Data Centre LOI
Sun Pharma Unloxcyt Gains Category 2A Status In NCCN Guidelines For Advanced Skin Cancer
Recent
RailTel Wins ₹47.4 Crore Haryana State Electronics Network Installation Contract
Quality Power Starts Production At New Coil Factory In Sangli
Venus Pipes Starts Pipe Spooling Early, Secures ₹185 Crore Data Centre LOI
Sun Pharma Unloxcyt Gains Category 2A Status In NCCN Guidelines For Advanced Skin Cancer
Frequently Asked Questions (FAQs)
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.